GlassScriptPhysician profile
Ricardo Lerma Solis
NPI 1891802732
$14,979.31
in general payments reported to CMS, 2019-2025
25 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,162 · 2020: $2,179 · 2021: $1,353 · 2022: $1,988 · 2023: $174 · 2024: $1,102 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434 · Travel and Lodging: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.21 |
| Travel and Lodging | $863.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,192.84 | 2019-2025 | Da Vinci Surgical System |
| Tela Bio, INC. | $2,185.53 | 2019-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| W. L. Gore & Associates, INC. | $1,355.80 | 2019 | |
| Stryker Corporation | $1,279.22 | 2019-2021 | |
| Biotissue Holdings INC. | $360.55 | 2024-2025 | |
| Medtronic, INC. | $349.28 | 2021-2025 | Signia |
| Davol INC. | $242.97 | 2019-2025 | Phasix Mesh |
| Pacira Pharmaceuticals Incorporated | $136.14 | 2022-2025 | Exparel |
| Takeda Pharmaceuticals U.S.A., INC. | $122.91 | 2022 | |
| Baxter Healthcare | $116.03 | 2021-2022 | |
| Hollister Incorporated | $114.87 | 2025 | New Image |
| Thd America, INC. | $100.02 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.03 | 2020-2022 | |
| Edwards Lifesciences Corporation | $49.18 | 2020-2024 | |
| Integra Lifesciences Corporation | $45.54 | 2021-2023 | Integra, Omnigraft, Integra Dermal Regeneration Template |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $43.44 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $41.10 | 2022 | |
| Covidien LP | $40.32 | 2019-2020 | |
| Dilon Technologies, INC. | $28.05 | 2024 | Hemoblast Bellows |
| Romark Laboratories, Lc | $22.90 | 2019 | |
| Medspira, LLC | $19.94 | 2022 | |
| Ethicon US, LLC | $19.07 | 2021 | |
| Mallinckrodt Enterprises LLC | $17.19 | 2019 | |
| Heron Therapeutics, INC. | $16.93 | 2022 | |
| Coloplast Corp | $13.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.